Abstracts tagged "scleroderma and systemic sclerosis"

Abstract Number: 727 • 2017 ACR/ARHP Annual Meeting
Survival and Clinical-Capillaroscopic Characteristics of French Canadian Systemic Sclerosis Patients: Analysis Based on Systemic Sclerosis Autoantibodies and the Novel Anti-BICD2 Autoantibody
Boyang Zheng¹, Michael Mahler², Jean-Luc Senécal³, France Joyal⁴ and Martial Koenig⁵, ¹Division of Internal Medicine, Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, QC, Canada, ²Research and Development, Inova Diagnostics, San Diego, CA, ³Rheumatology, Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, QC, Canada, ⁴Internal Medicine, Centre Hospitalier de l'Université de Montréal (CHUM), Montreal, QC, Canada, ⁵Internal Medicine, Hôpital Notre-Dame du CHUM, Montréal, QC, Canada
Background/Purpose: Systemic sclerosis (SSc) autoantibodies (aAbs) are invaluable for SSc diagnosis and prognosis. Anti-centromere (ACA), anti-topoisomerase I (ATA) and anti-RNA polymerase III (RNAP) have been…
Abstract Number: 2691 • 2017 ACR/ARHP Annual Meeting
Increased Circulating Cadherin-11 Levels in Patients with Systemic Sclerosis
Bochra Jandali¹, Grace H. Lo², Robert L. Welschhans³, Julio Charles⁴, Ramona Mihu^3,5, Maureen D. Mayes⁶, Shervin Assassi⁷ and Sandeep K. Agarwal³, ¹Medicine, Section of Immmunology, Allergy and Rheumatology, Baylor College of Medicine, Houston, TX, ²Immunology, Allergy, Rheumatology, Baylor College of Medicine, Houston, TX, ³Medicine, Section of Immunology, Allergy and Rheumatology, Baylor College of Medicine, Houston, TX, ⁴Internal Medicine/Rheumatology, University of Texas - Houston Medical School, Houston, TX, ⁵Medicine, Division of Rheumatology, Houston Methodist Hospital, Houston, TX, ⁶Department of Internal Medicine - Rheumatology, University of Texas-McGovern Medical School, Houston, TX, ⁷University of Texas McGovern Medical School, Houston, TX
Background/Purpose: Systemic sclerosis (SSc) is a chronic systemic disease characterized by skin and internal organs fibrosis along with vasculopathy. Previous studies have reported increased cadherin-11…
Abstract Number: 728 • 2017 ACR/ARHP Annual Meeting
Symptoms of Autonomic Dysfunction in Systemic Sclerosis Assessed By the Compass-31 Questionnaire
Brittany Adler¹, James Russell², Laura K. Hummers³ and Zsuzsanna McMahan⁴, ¹Rheumatology, Johns Hopkins University, Baltimore, MD, ²Neurology, Anatomy and Neurobiology, University of Maryland School of Medicine, Baltimore, MD, ³Medical and Rheumatology, Johns Hopkins University, Baltimore, MD, ⁴Department of Internal Medicine, Johns Hopkins University, Baltimore, MD
Background/Purpose: Autonomic dysfunction is a known complication of systemic sclerosis (SSc) and can affect vascular tone, gastrointestinal (GI) motility, and heart rate and blood pressure…
Abstract Number: 2695 • 2017 ACR/ARHP Annual Meeting
Latent Profile Analysis-Derived Typologies of Systemic Sclerosis Patients Using Body Image Indicators: A Scleroderma Patient-Centered Intervention Network (SPIN) Cohort Study
Shadi Gholizadeh¹, Linda Kwakkenbos², Marie-Eve Carrier³, Sarah D. Mills¹, Rina S. Fox⁴, Lisa Jewett², Karen Gottesman⁵, Scott Roesch¹, Brett D. Thombs² and Vanessa L. Malcarne¹, ¹SDSU/UC San Diego Joint Doctoral Program in Clinical Psychology, San Diego, CA, ²McGill University; Lady David Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada, ³McGill University, Montreal, QC, Canada, ⁴Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁵Scleroderma Foundation, Los Angeles, CA
Background/Purpose: A common and distressing manifestation of systemic sclerosis (SSc, or scleroderma) is disfigurement in socially relevant areas of the body, including the face and…
Abstract Number: 733 • 2017 ACR/ARHP Annual Meeting
Ethnic Variation in Systemic Sclerosis Morbidity and Mortality
Sindhu Johnson¹, Zareen Ahmad² and Haifa Al Sheikh³, ¹Division of Rheumatology, Toronto Western Hospital, Mount Sinai Hospital, Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, ²Toronto Scleroderma Program, Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ³Division of Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada
Background/Purpose: Systemic sclerosis (SSc) is an uncommon connective tissue disease characterized by pathological skin thickening and can involve multiple internal organs. Ethnic variations in SSc…
Abstract Number: 2696 • 2017 ACR/ARHP Annual Meeting
Things Left Unsaid: Important Topics That Are Not Discussed between Patients with Systemic Sclerosis, Their Carers and Their Healthcare Professionals
Christopher Denton¹, Bee Laird², Lizette Moros³ and José Luis Luna Flores⁴, ¹Department of Rheumatology, University College London, Royal Free Hospital, London, United Kingdom, ²Reframe Research, East Sussex, United Kingdom, ³Boehringer-Ingelheim, Ingelheim, Germany, ⁴Boehringer Ingelheim, Ingelheim, Germany
Background/Purpose: Systemic sclerosis (SSc) is a serious rare condition that can be complicated by internal organ damage including interstitial lung fibrosis (SSc-ILD), which is a…
Abstract Number: 737 • 2017 ACR/ARHP Annual Meeting
Dynamic Prediction of Pulmonary Hypertension Development in Systemic Sclerosis Patients Using Landmark Analysis – Comparison of Two Models
Svetlana I. Nihtyanova¹, Voon H. Ong², Emma C. Derrett-Smith³, Benjamin Schreiber⁴, J. Gerry Coghlan⁴, Bianca DeStavola⁵ and Christopher Denton⁶, ¹Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom, ²Rheumatology, UCL Division of Medicine, London, United Kingdom, ³Centre for Rheumatology and Connective Tissue Diseases, UCL Division of Medicine, London, United Kingdom, ⁴National Pulmonary Hypertension Service, Royal Free Hospital, London, United Kingdom, ⁵Faculty of Population Health Sciences, UCL Institute of Child Health, London, United Kingdom, ⁶Department of Rheumatology, University College London, Royal Free Hospital, London, United Kingdom
Background/Purpose: Pulmonary hypertension (PH) contributes substantially to systemic sclerosis (SSc)-related morbidity and mortality. It tends to develop later in the disease, creating an opportunity for…
Abstract Number: 2982 • 2017 ACR/ARHP Annual Meeting
Morbidity and Mortality of Scleroderma in African Americans
Duncan F. Moore¹, Elisabeth Kramer¹, Rami Eltaraboulsi² and Virginia D. Steen¹, ¹Division of Rheumatology, Department of Medicine, MedStar Georgetown University Hospital, Washington, DC, ²MedStar Georgetown University Hospital, Washington, DC
Background/Purpose: Retrospective cohorts have demonstrated that African Americans (AAs) with scleroderma are more likely to have severe disease and higher mortality than non-AAs. A prior…
Abstract Number: 761 • 2017 ACR/ARHP Annual Meeting
Increased Expression of the TNF Superfamily Member LIGHT/TNFSF14 and Its Receptor (TNFRSF14) in Patients with Systemic Sclerosis
Otylia Kowal-Bielecka¹, Ewa Gindzienska-Sieskiewicz¹, Oliver Distler², Joanna Reszec³, Suzana Jordan², Pawel Bielecki⁴, Andzrzej Sieskiewicz⁴, Agnieszka Sulik¹ and Krzysztof Kowal^5,6, ¹Department of Rheumatology and Internal Medicine, Medical University of Bialystok, Bialystok, Poland, ²Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ³Department of Medical Pathomorphology, Department of Medical Pathomorphology, Medical University of Bialystok, Bialystok, Poland, ⁴Department of Otolaryngology, Medical University of Bialystok, Bialystok, Poland, ⁵Department of Allergology and Internal Medicine, Medical University of Bialystok, Bialystok, Poland, ⁶Department of Experimental Allergology and Immunology, Medical University of Bialystok, Bialystok, Poland
Background/Purpose: The TNF Superfamily member LIGHT (TNFSF14) regulates immune response and angiogenesis. Moreover, recent studies indicate that interactions of LIGHT with its receptor, TNFRSF14, might…
Abstract Number: 775 • 2017 ACR/ARHP Annual Meeting
Transcriptome Sequencing Reveals Genetic Polymorphisms Associated with Ssc Gene Expression Subtypes
Guoshuai Cai¹, Bhaven K. Mehta², Mengqi Huang², Jennifer Franks¹, Tammara A. Wood¹, Kathleen D. Kolstad³, Marianna Stark⁴, Antonia Valenzuela⁵, David Fiorentino⁶, Robert W. Simms⁷, Nicole Orzechowski⁸, Lorinda Chung⁹ and Michael L. Whitfield², ¹Department of Molecular and Systems Biology, Geisel School of Medicine at Dartmouth, Hanover, NH, ²Molecular and Systems Biology, Geisel School of Medicine at Dartmouth, Hanover, NH, ³Rheumatology, Stanford University Medical Center, Stanford, CA, ⁴Stanford University, Stanford, CA, ⁵Immunology and Rheumatology, Stanford University, Palo Alto, CA, ⁶Department of Dermatology, Stanford University School of Medicine, Palo Alto, CA, ⁷Rheumatology, Boston University School of Medicine, Boston, MA, ⁸Dartmouth-Hitchcock Medical Center, Lebanon, NH, ⁹Rheumatology, Stanford University Medical Center, Palo Alto, CA
Background/Purpose: Systemic sclerosis (SSc) is a complex disease characterized by substantial genotypic and phenotypic heterogeneity. Four molecular gene expression subsets have been identified from SSc…
Abstract Number: 919 • 2017 ACR/ARHP Annual Meeting
HLA Type Imputation in the Genome Research in African American Scleroderma Patients (GRASP) Cohort Reveals Strong Associations of African Ancestry MHC Class II Types with Scleroderma and Lack of Class I HLA Type Associations
Elaine F. Remmers¹, Pravitt Gourh², Steven Boyden³, Nadia D. Morgan⁴, Ami A. Shah⁴, Adebowale Adeyemo¹, Amy Bentley¹, Mary A. Carns⁵, Settara C. Chandrasekharappa¹, Lorinda Chung⁶, Lindsey A. Criswell⁷, Chris T. Derk⁸, Robyn T. Domsic⁹, Ayo Doumatey¹, Heather Gladue¹⁰, Avram Goldberg¹¹, Jessica K. Gordon¹², Vivien M Hsu¹³, Reem Jan¹⁴, Dinesh Khanna¹⁵, Maureen D. Mayes¹⁶, Thomas A. Medsger Jr.¹⁷, Paula S. Ramos¹⁸, Marcin A. Trojanowski¹⁹, Lesley A. Saketkoo²⁰, Elena Schiopu¹⁵, Victoria K. Shanmugam²¹, Daniel Shriner¹, Richard M. Silver²², Virginia D. Steen²³, Antonia Valenzuela²⁴, John Varga²⁵, Charles Rotimi¹, Fredrick M. Wigley²⁶, Francesco Boin²⁷ and Daniel L. Kastner²⁸, ¹National Institutes of Health (NIH), National Human Genome Research Institute, Bethesda, MD, ²NIAMS-Rheumatology, National Institutes of Health (NIH), National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, ³National Institutes of Health (NIH), National Institute on Deafness and Other Communication Disorders, Bethesda, MD, ⁴Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Northwestern University, Feinberg School of Medicine Scleroderma Program, Chicago, IL, ⁶Rheumatology, Stanford University Medical Center, Palo Alto, CA, ⁷Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ⁸Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁹Rheumatology, University of Pittsburgh, Pittsburgh, PA, ¹⁰Rheumatology, Arthritis and Osteoporosis Consultants of the Carolinas, Charlotte, NC, ¹¹NYU Langone Medical Center, New York, NY, ¹²Rheumatology, Hospital for Special Surgery, New York, NY, ¹³University of Medicine and Dentistry of New Jersey--Robert Wood Johnson Medical School, New Brunswick, NJ, ¹⁴Medicine, Rheumatology, University of Chicago, Chicago, IL, ¹⁵University of Michigan, Ann Arbor, MI, ¹⁶University of Texas McGovern Medical School, Houston, TX, ¹⁷Department of Medicine/Rheumatology, University of Pittsburgh, Pittsburgh, PA, ¹⁸Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC, ¹⁹Boston University School of Medicine, Boston, MA, ²⁰Rheumatology, Tulane University School of Medicine, New Orleans, LA, ²¹Rheumatology, The George Washington University, Washington, DC, ²²Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, SC, ²³Rheumatology, MedStar Georgetown University Hospital, Washington, DC, ²⁴Stanford University School of Medicine, Stanford, CA, ²⁵Rheumatology and Dermatology, Northwestern University, Feinberg School of Medicine Scleroderma Program, Chicago, IL, ²⁶Rheum Div/Mason F Lord, Johns Hopkins University, Baltimore, MD, ²⁷Rheumatology, University California, San Francisco, San Francisco, CA, ²⁸Inflammatory Disease Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD
Background/Purpose: The Genome Research in African American Scleroderma Patients (GRASP) consortium was created to obtain a collection of African American (AA) scleroderma patients to facilitate…
Abstract Number: 1248 • 2017 ACR/ARHP Annual Meeting
Evaluation of Validated Patient Reported Outcome Measures to Assess Sensitivity to Change in Patients with Systemic Sclerosis and Gastroesophageal Reflux Disease —a Scleroderma Clinical Trials Consortium Collaborative Project
Zsuzsanna McMahan¹, Tracy M. Frech², David Lim³, Veronica J. Berrocal⁴, Cosimo Bruni⁵, Marco Matucci-Cerinic⁶, Vanessa Smith⁷, Karin Melsons⁸, Susanna Proudman⁹, Jinyu Zhang¹⁰, Fabian A Mendoza¹¹, Melanie Woods³ and Dinesh Khanna³, ¹Department of Internal Medicine, Johns Hopkins University, Baltimore, MD, ²Division of Rheumatology, University of Utah, Salt Lake City, UT, ³University of Michigan, Ann Arbor, MI, ⁴Div of Rheumatology, University of Michigan, Ann Arbor, MI, ⁵Department of Experimental and Clinical Medicine, Division of Rheumatology, University of Florence, Firenze, Italy, ⁶Dept of Medicine/Div of Rheum, University of Florence, Firenze, Italy, ⁷Faculty of Internal Medicine, Ghent University, Ghent, Belgium, ⁸Ghent University, Gent, Belgium, ⁹Discipline of Medicine, University of Adelaide, Adelaide, Australia, ¹⁰Thomas Jefferson University, Philadelphia, PA, ¹¹Jefferson Institute of Molecular Medicine and Scleroderma Center, Rheumatology Division, Department of Medicine, Thomas Jefferson University, Philadelphia, PA
Background/Purpose: The UCLA SCTC GIT 2.0 and NIH PROMIS GI Symptoms Scales are validated in scleroderma to assess patient-reported gastrointestinal (GI) involvement. We sought to…
Abstract Number: 1676 • 2017 ACR/ARHP Annual Meeting
Improving Sensitivity to Change of the Modified Rodnan Skin Score over Time
Annel M. Fernandez¹, Robert F. Spiera², Jackie Szymonifka² and Jessica K. Gordon², ¹Medicine- Rheumatology/ Research, Hospital For Special Surgery, New York, NY, ²Rheumatology, Hospital for Special Surgery, New York, NY
Background/Purpose: The Modified Rodnan Skin Score (MRSS) assesses global dermal thickness through the examination of 17 body areas scored by clinical palpation using a 4…
Abstract Number: 6L • 2016 ACR/ARHP Annual Meeting
Myeloablative Autologous Transplantation of CD34+ -Selected Hematopoietic Stem Cells (HSCT) Vs Monthly Intravenous Cyclophosphamide (CYC) for Severe Scleroderma with Internal Organ Involvement: Outcomes of a Randomized North American Clinical Trial
Keith Sullivan¹, Lynette Keyes-Elstein², Peter McSweeney³, Ashley Pinckney², Beverly Welch⁴, Maureen D Mayes⁵, Richard Nash³, Leslie J. Crofford⁶, Sharon Castina², Linda Griffith⁷, Ellen Goldmuntz⁸ and Daniel E. Furst⁹, ¹Duke University, Durham, NC, ²Rho, Inc, Chapel Hill, NC, ³Colorado Blood Cancer Institute, Denver, CO, ⁴6610 Rockledge Dr., NIAID/NIH, Bethesda, MD, ⁵Department of Internal Medicine - Rheumatology, University of Texas-McGovern Medical School, Houston, TX, ⁶Medicine, Vanderbilt University Medical Center, Nasville, TN, ⁷NIAID, NIH, Bethesda, MD, ⁸NIAID, National Institutes of Health, Bethesda, MD, ⁹David Geffen School of Medicine at UCLA, Los Angeles, CA
Background/Purpose: Therapeutic options for diffuse cutaneous systemic sclerosis (dcSSc) are limited. The Scleroderma: Cyclophosphamide or Transplantation (SCOT) trial was a multicenter study designed to…
Abstract Number: 1880 • 2016 ACR/ARHP Annual Meeting
A Large Proportion of Patients in an Early Systemic Sclerosis-Associated Interstitial Lung Disease Cohort Have Coexisting Pulmonary Hypertension
Amber Young¹, Caitlyn Fisher¹, Rajaie Namas², Holly Wilhalme³ and Dinesh Khanna⁴, ¹Department of Internal Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, MI, ²Department of Medicine [Division of Rheumatology], University of Michigan, Ann Arbor, MI, ³University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁴University of Michigan, Ann Arbor, MI
Background/Purpose: Systemic Sclerosis (SSc) is a multi-organ system disease manifested by fibrosis, vascular damage and dysregulation of the immune system. The leading causes of death…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.